Related references
Note: Only part of the references are listed.2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease
B. Besse et al.
ANNALS OF ONCOLOGY (2014)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Efficacy of Chemotherapy for Advanced Non-Small Cell Lung Cancer with Idiopathic Pulmonary Fibrosis
Naohiro Watanabe et al.
RESPIRATION (2013)
Association of Computed Tomography-detected Pulmonary Interstitial Changes with Severe Radiation Pneumonitis for Patients Treated with Thoracic Radiotherapy
Naoko Sanuki et al.
JOURNAL OF RADIATION RESEARCH (2012)
Safety and effectiveness of pemetrexed in patients with malignant pleural mesothelioma based on all-case drug-registry study
Kozo Kuribayashi et al.
LUNG CANCER (2012)
2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer
Christopher G. Azzoli et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The Risk of Cytotoxic Chemotherapy-Related Exacerbation of Interstitial Lung Disease with Lung Cancer
Hirotsugu Kenmotsu et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias
Yuji Minegishi et al.
LUNG CANCER (2011)
Phase III Trial Comparing Oral S-1 Plus Carboplatin With Paclitaxel Plus Carboplatin in Chemotherapy-Naive Patients With Advanced Non-Small-Cell Lung Cancer: Results of a West Japan Oncology Group Study
Isamu Okamoto et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Severe Interstitial Lung Disease Associated with Amrubicin Treatment
Kiyotaka Yoh et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Exacerbation of Idiopathic Interstitial Pneumonias Associated with Lung Cancer Therapy
Yuji Minegishi et al.
INTERNAL MEDICINE (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Interstitial lung disease in Japanese patients with lung cancer - A cohort and nested case-control study
Shoji Kudoh et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
Acute exacerbations of idiopathic pulmonary fibrosis
Harold R. Collard et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan
Y. Ohe et al.
ANNALS OF ONCOLOGY (2007)
Interstitial lung disease associated with drug therapy
P Camus et al.
BRITISH JOURNAL OF CANCER (2004)
Severe interstitial pneumonitis associated with docetaxel administration
WL Read et al.
CANCER (2002)
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
JH Schiller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer
Y Ohe et al.
EUROPEAN JOURNAL OF CANCER (2001)
Share Paper
